Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

The price of Bitcoin is reflective of a previous cycle, remaining near the golden Fibonacci retracement point and pointing to a future breakout. Bitcoin is exhibiting the reiteration of a price ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Recursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its ...

Fibonacci sequences are sequences of numbers whose first two elements are 0, 1, and such that, starting from the third number, every element of the sequence is the sum of the previous two. They are of ...

We uphold a strict editorial policy that focuses on factual accuracy, relevance, and impartiality. Our in-house created content is meticulously reviewed by a team of seasoned editors to ensure ...

What's going on with Recursion? Cramer stated on Mad Money at the end of last week's trading that Recursion's stock performance has "been disastrous" since the company's management appeared on his ...